SEKHRI PAUL J 4

What Happened

• Paul J. Sekhri, President, CEO and Executive Chairperson of vTv Therapeutics (VTVT), was granted a derivative equity award for 140,000 shares on 2026-02-17. The grant is reported at $36.92 per share, for a notional value of $5,168,800.
• This filing reports an award/acquisition (derivative) — not an open-market purchase or sale — and does not reflect an immediate disposition of shares.

Key Details

• Transaction date: 2026-02-17; Filing date: 2026-02-18 (appears timely).
• Instrument/amount: 140,000 derivative shares at $36.92 per share; total reported value $5,168,800.
• Vesting: 25% vests on the first anniversary of the grant date, then in equal quarterly installments thereafter (footnote F1).
• Shares owned after transaction: Not disclosed in this Form 4.
• No indication of a 10b5-1 plan, tax withholding, cashless exercise, or sale in this filing.

Context

• This is a compensation-related equity award (a derivative grant). Such awards are commonly part of executive compensation and do not, by themselves, indicate that the insider bought or sold stock in the open market.
• If these are stock options or similar derivatives, Sekhri will need to satisfy vesting and any exercise conditions before becoming ordinary shares that can be sold.